SCHEDULE 13G/A: Lance Friedman Discloses 8.25% Passive Stake in Aspire Biopharma Holdings, Inc.
Beneficial Ownership Report
Lance Friedman has filed an Amendment No. 7 to Schedule 13G, disclosing a beneficial ownership of 8.25% of Aspire Biopharma Holdings, Inc.'s common stock as of April 21, 2025.
Summary
- Lance Friedman beneficially owns 4,035,733 shares of common stock in Aspire Biopharma Holdings, Inc.
- This ownership represents 8.25% of the total class of securities.
- Friedman holds sole voting and sole dispositive power over all 4,035,733 shares.
- The shares include holdings by Blackstone Capital Advisors, Inc. (1,680,886 shares), Cobra Alternative Strategies LLC (1,692,347 shares), and Thor Special Situations LLC (662,500 shares).
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's performance or outlook.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Aspire Biopharma Holdings, Inc., indicating a passive investment stance by Lance Friedman.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake in a biopharma company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that Aspire Biopharma Holdings, Inc. is a publicly traded entity in the sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by Lance Friedman and associated entities, confirming no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 04/21/2025 | Date of Event Which Requires Filing of this Statement |
| 04/23/2025 | Date of Schedule 13G filing |
Keywords
Aspire Biopharma Holdings, Lance Friedman, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Biopharma, Investment, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.